SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Mar 16, 2006

Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: March 16, 2006 · CIK: 0001213037 · Accession: 0001321543-06-000144

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-127071

Date

March 16, 2006

Author

Not clearly detected

Form

CORRESP

Company

Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)

Letter

Acceleration Request

Xenomics, Inc.

Lexington Avenue, Suite 1701

New York, New York 10170

March 16,

VIA FACSIMILE AND EDGAR

United States Securities

and Exchange Commission

F Street, NE

Washington, D.C. 20549

Attention: William Bennett, Esq.

Re: Xenomics, Inc.

Registration Statement on Form SB-2

File No. 333-127071

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Xenomics, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Thursday, March 16, 2006, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

XENOMICS, INC.

By: /s/ L. David Tomei

Name: L. David Tomei

Title: Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

      Acceleration Request

    Xenomics,
      Inc.

    420
      Lexington Avenue, Suite 1701

    New
      York, New York 10170

    March
      16,
      2006

    VIA
      FACSIMILE AND EDGAR

    United
      States Securities

    and
      Exchange Commission

    100
      F
      Street, NE

    Washington,
      D.C. 20549

    Attention:
      William Bennett, Esq.

            Re:
             Xenomics,
              Inc.

            Registration
              Statement on Form SB-2

              File
                No. 333-127071

    Ladies
      and Gentlemen:

    Pursuant
      to Rule 461 of the General Rules and Regulations under the Securities Act of
      1933, as amended (the “Act”), Xenomics, Inc. (the “Company”) respectfully
      requests that the effective date of the registration statement referred to
      above
      be accelerated so that it will become effective at 4:00 p.m., Eastern Standard
      Time, on Thursday, March 16, 2006, or as soon thereafter as possible. The
      Company acknowledges that: 1) should the Commission or the staff, acting
      pursuant to delegated authority, declare the filing effective, it does not
      foreclose the Commission from taking any action with respect to the filing;
      2)
      the action of the Commission or the staff, acting pursuant to delegated
      authority, in declaring the filing effective, does not relieve the Company
      from
      its full responsibility for the adequacy and accuracy of the disclosure in
      the
      filing; and 3) the Company may not assert this action as defense in any
      proceeding initiated by the Commission or any person under the federal
      securities laws of the United States.

              XENOMICS,
                INC.

            By:
            /s/ L.
              David Tomei

              Name:
              L. David Tomei

              Title:
                Chief Executive Officer

SecProbe.io